argenx to Host Myositis R&D Webinar on June 23, 2026
Stocks in this Quantisnow insightHealth Care
Historical context for ARGX
Across the 23 sessions after earlier ARGX headlines, the stock closed higher 10 times and lower 13 times, with a median move of 1.5% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | ARGX | SPY |
|---|---|---|---|
| May 27, 2026 | argenx to Present at Upcoming Investor Conferences | +1.5% | -0.0% |
| May 11, 2026 | argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG | +4.0% | +0.2% |
| May 7, 2026 | argenx Reports First Quarter 2026 Financial Results and Provides Business Updateand 2 other headlines that session | -2.5% | -0.3% |
| Apr 30, 2026 | argenx to Report First Quarter 2026 Financial Results and Business Update on May 7, 2026 | +0.7% | +1.0% |
| Apr 20, 2026 | argenx Brings Neuromuscular Leadership to AAN 2026 with New Data Supporting Broader VYVGART Use Across MG and CIDP | -1.7% | -0.2% |
| Mar 23, 2026 | argenx announces Annual General Meeting of Shareholders on May 6, 2026 | +2.7% | +1.1% |
Quantisnow market dataNASDAQ
ARGX
argenx SE
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Listed since
- 2017
Get push alerts for ARGX
Full ARGX profile on Quantisnow Follow ARGX and get a push notification the moment its next story breaks.